Read twice and referred to the Committee on Finance.
This bill (Skin Substitute Access and Payment Reform Act of 2025) amends Medicare payment rules for skin substitute products under title XVIII of the Social Security Act. Beginning January 1, 2026, Medicare Part B payments for skin substitute products would be set using a single, volume-weighted average payment allowance limit based on product-level ASP/payment data and units billed in Q4 2023, with annual CPI-U updates.
Use of clinical evidence: liberals and centrists worry the restriction on CMS denying coverage based solely on clinical evidence undermines evidence-based decisions; conservatives see it as creating uncertainty—both sides diverge on its meaning and impact.
Relative to its intended legislative type, this bill is a substantive statutory amendment to Medicare payment rules that is specific in its core payment formula, product definition, and implementation dates, but it leaves material operational and fiscal details unaddressed.
This bill (Skin Substitute Access and Payment Reform Act of 2025) amends Medicare payment rules for skin substitute products under title XVIII of the Social Security Act.
Beginning January 1, 2026, Medicare Part B payments for skin substitute products would be set using a single, volume-weighted average payment allowance limit based on product-level ASP/payment data and units billed in Q4 2023, with annual CPI-U updates.
The Secretary must create a consolidated billing and payment code for all skin substitute products and apply uniform "reasonable and necessary" criteria to them, with a limitation that the Secretary may not deny coverage based solely on analysis of clinical evidence.
On content alone the bill is a targeted Medicare payment reform with a plausible cost-saving rationale and technical structure that could appeal to both chambers. However, it contains provisions that limit CMS' evidence-based coverage discretion and remove manufacturer reporting obligations, which are likely to provoke concentrated opposition from industry and possibly from groups emphasizing evidence-based coverage and patient safety. The absence of built-in compromise mechanisms and a tight implementation timeline further reduce its near-term viability without amendments or negotiated offsets.
Relative to its intended legislative type, this bill is a substantive statutory amendment to Medicare payment rules that is specific in its core payment formula, product definition, and implementation dates, but it leaves material operational and fiscal details unaddressed.
Use of clinical evidence: liberals and centrists worry the restriction on CMS denying coverage based solely on clinical evidence undermines evidence-based decisions; conservatives see it as creating uncertainty—both sides diverge on its meaning and impact.
These are examples from the analysis, not a ranked list of the most-affected groups.
Use of clinical evidence: liberals and centrists worry the restriction on CMS denying coverage based solely on clinical evidence undermines evidence-based decisions; conservatives see it as creating uncertainty—both sid…
A mainstream progressive would likely welcome the bill's goal of containing Medicare spending on skin substitutes and ensuring access for beneficiaries, because it attempts to eliminate incentives that favor more expensive products with similar clinical effects.
However, they would be concerned about provisions that limit CMS's ability to use clinical evidence to determine coverage and about the removal of ASP reporting requirements, which could reduce pricing transparency and complicate Medicaid rebate interactions.
They would also focus on ensuring patient safety and that coverage rules do not enable lower-quality products to displace clinically superior options.
A centrist/moderate would see merit in standardizing payments and reducing incentives that encourage use of higher-priced skin substitute products when clinical benefit is similar.
They would appreciate the administrative simplification from a consolidated billing code and a predictable, CPI-U indexed payment update.
At the same time, they would be concerned about constraints on CMS's ability to use clinical evidence to inform coverage and the removal of ASP reporting, both of which could impede oversight or adaptability.
A mainstream conservative would appreciate efforts to curb Medicare spending growth and reduce reporting burdens on manufacturers (the bill removes an ASP reporting requirement).
However, they would be skeptical of a federal rule that effectively sets a single averaged Medicare payment for a class of products, viewing it as government price-setting that could distort markets and discourage innovation or supplier entry.
They may also worry that a consolidated code could reduce competition and that the restrictions on CMS coverage determinations introduce regulatory confusion.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is a targeted Medicare payment reform with a plausible cost-saving rationale and technical structure that could appeal to both chambers. However, it contains provisions that limit CMS' evidence-based coverage discretion and remove manufacturer reporting obligations, which are likely to provoke concentrated opposition from industry and possibly from groups emphasizing evidence-based coverage and patient safety. The absence of built-in compromise mechanisms and a tight implementation timeline further reduce its near-term viability without amendments or negotiated offsets.
The bill has not accumulated any surfaced votes yet.
Use of clinical evidence: liberals and centrists worry the restriction on CMS denying coverage based solely on clinical evidence undermines…
On content alone the bill is a targeted Medicare payment reform with a plausible cost-saving rationale and technical structure that could a…
Relative to its intended legislative type, this bill is a substantive statutory amendment to Medicare payment rules that is specific in its core payment formula, product definition, and implementation dates, but it leav…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.